Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ADAM17 | P78536 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4867956 | 1.00 | METAP2 (0.38) | METAP2NPC1RAB9ASMN1; SMN2NAMPT | |
| SCHEMBL4867943 | 1.00 | METAP2 (0.38) | METAP2NPC1RAB9ASMN1; SMN2NAMPT | |
| SCHEMBL4866782 | 0.90 | METAP2 (0.36) | METAP2NPC1RAB9ANAMPTALDH1A1 | |
| SCHEMBL4866785 | 0.90 | METAP2 (0.36) | METAP2NPC1RAB9ANAMPTALDH1A1 | |
| SCHEMBL4866777 | 0.90 | METAP2 (0.36) | METAP2NPC1RAB9ANAMPTALDH1A1 | |
| SCHEMBL4866773 | 0.90 | METAP2 (0.36) | METAP2NPC1RAB9ANAMPTALDH1A1 | |
| SCHEMBL4864653 | 0.88 | METAP2 (0.39) | METAP2NPC1RAB9ASMN1; SMN2NAMPT | |
| SCHEMBL4866445 | 0.88 | METAP2 (0.39) | METAP2NPC1RAB9ASMN1; SMN2NAMPT | |
| SCHEMBL4864657 | 0.88 | METAP2 (0.39) | METAP2NPC1RAB9ASMN1; SMN2NAMPT | |
| SCHEMBL4864631 | 0.86 | LMNA (0.40) | METAP2NAMPTALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332485-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORP (US) | 2008-02-19 | — | — | US | disclosed |
| US-20060160802-A1 | Peptide deformylase inhibitors | GLAXO GROUP LIMITED | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160802-A1 | Peptide deformylase inhibitors | PDF, PEPD, DPEP1 | METAP2 757/4885NPC1 1328/4885RAB9A 2101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.